Wall Street analysts expect that Aimmune Therapeutics Inc (NASDAQ:AIMT) will announce ($1.05) earnings per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Aimmune Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.92) and the lowest estimate coming in at ($1.19). Aimmune Therapeutics posted earnings of ($1.01) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 4%. The firm is scheduled to report its next quarterly earnings report on Thursday, August 13th.
According to Zacks, analysts expect that Aimmune Therapeutics will report full-year earnings of ($4.44) per share for the current financial year, with EPS estimates ranging from ($5.20) to ($3.98). For the next fiscal year, analysts expect that the company will post earnings of ($2.80) per share, with EPS estimates ranging from ($3.73) to ($2.25). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Aimmune Therapeutics.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, May 11th. The biotechnology company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.16). The company had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.34 million. During the same quarter last year, the firm posted ($0.87) earnings per share. The firm’s revenue for the quarter was up NaN% compared to the same quarter last year.
A number of analysts have recently weighed in on the stock. Cowen assumed coverage on shares of Aimmune Therapeutics in a research report on Monday, July 13th. They issued an “outperform” rating and a $35.00 target price on the stock. BidaskClub cut shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 10th. Wedbush reiterated a “buy” rating and issued a $66.00 price target on shares of Aimmune Therapeutics in a research note on Wednesday, May 13th. Stifel Nicolaus restated a “hold” rating and set a $20.00 target price (down previously from $32.00) on shares of Aimmune Therapeutics in a research note on Monday, May 11th. Finally, Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research note on Friday, May 29th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $38.08.
A number of large investors have recently made changes to their positions in the business. Huntington National Bank purchased a new stake in shares of Aimmune Therapeutics in the first quarter valued at approximately $29,000. Marshall Wace North America L.P. purchased a new stake in shares of Aimmune Therapeutics in the first quarter valued at approximately $32,000. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Aimmune Therapeutics by 45.1% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,579 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 491 shares in the last quarter. US Bancorp DE increased its position in shares of Aimmune Therapeutics by 22.9% in the first quarter. US Bancorp DE now owns 6,222 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 1,158 shares in the last quarter. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of Aimmune Therapeutics during the fourth quarter worth approximately $96,000. 72.43% of the stock is owned by institutional investors.
Shares of Aimmune Therapeutics stock opened at $15.60 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.10 and a quick ratio of 8.01. The company’s fifty day simple moving average is $17.23 and its two-hundred day simple moving average is $20.81. Aimmune Therapeutics has a 12-month low of $10.09 and a 12-month high of $37.00.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Featured Article: What does an inverted yield curve signify?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.